Thromboelastography is a technique for determining the effectiveness of blood coagulation. Nonetheless, its use in resuscitations in emergency rooms, intensive care units, and delivery rooms is increasing. The test is mostly used in surgery and anesthesia. TEG (thromboelastography) is a non-invasive technique for determining the clotting propensity of whole blood. The goal of this in vitro test is to detect and quantify dynamic changes in the viscoelastic characteristics of a blood sample that occur during clotting under mild shear stress. Since more industry players are releasing products, the global thromboelastography market is anticipated to grow throughout the course of the projected period. Over the forecast period, an increase in R&D activities is anticipated to fuel market expansion for thromboelastography worldwide.
The global market for Thromboelastography is anticipated to expand at a CAGR of 7.1% from 2022 to 2030.
Prominent Players in the Thromboelastography Industry:
1. Lepu Medical Technology (Beijing) Co., Ltd.
Lepu Medical Technology (Beijing) Co., Ltd. was founded in 1999 and headquartered in Beijing, China. It operates in more than 80 countries.
2. Render Biotech Co.
Render Biotech Co. was founded in 2016 and headquartered in Guangming, Shenzhen. It operates in Asia and distributors around the globe. On MEDICA 2022 in November 2022, Render announced the first highest throughput completely automated Thromboelastography IHTEG series by Render independent research and development.
3. Haemonetics Corporation
Haemonetics Corporation is a global provider of blood and plasma supplies and services. It was founded in 1971 and headquartered in Massachusetts, USA. It operates in 50 countries. For the length of the COVID-19 public health emergency, Haemonetics Corporation, a worldwide medical technology company focused on providing creative medical solutions to enhance patient outcomes, affirms its support for updated FDA recommendations on the use of viscoelastic testing in January 2021. Haemonetics is moving fast to update the indications for the TEG® 5000 and TEG® 6s hemostasis analyzers, as well as any associated assays, in compliance with FDA recommendations by revising product labeling and usage instructions. Healthcare professionals will be able to start using TEG® devices throughout the pandemic to enhance patient care.
4. TA Instruments
TA Instruments was founded in 1990 and headquartered in New Castle, Delaware. It operates in 35 countries.
5. HemaCore LLC
HemaCore LLC was founded in 2010 and headquartered in Russian Federation, Moscow City. It operates in.
6. 5-Diagnostics
5-Diagnostics was founded in 2012 and headquartered in Switzerland. It operates in.
7. Xenometrix AG
Xenometrix AG was founded in 1995 and headquartered in Allschwil, Switzerland. It operates across the world.
8. Framar Hemologix srl
Framar Hemologix srl was founded in 1997 and headquartered in Italy. It operates in Italy and abroad.
9. Instrumentation Laboratory
Instrumentation Laboratory was founded in 1959 and headquartered in Massachusetts, the US. It operates in more than 30 countries.
10. Medirox AB
Medirox AB was founded in 1998 and headquartered in Soedermanland, Sweden. It operates in.
*Definition: Thromboelastography (TEG) is a non-invasive technique that quantifies the clotting potential of whole blood. This in vitro test's objective is to spot and quantify dynamic changes in a blood sample's viscoelastic properties that take place during clotting under mild shear stress. The test is carried out using a specially designed machine called a thromboelastography.
